Drug Information

Drug General Information
Drug ID
D01UDS
Former ID
DIB005017
Drug Name
CNV-2197944
Synonyms
GSK-2197944; Cav2.2 channel blocker (chronic pain), GlaxoSmithKline/Convergence Pharmaceuticals
Indication Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] Phase 2 [524280]
Company
GlaxoSmithKline plc
Structure
Download
2D MOL

3D MOL
Target and Pathway
Target(s) Voltage-dependent N-type calcium channel Target Info Blocker [550563]
KEGG Pathway MAPK signaling pathway
Calcium signaling pathway
Synaptic vesicle cycle
Retrograde endocannabinoid signaling
Cholinergic synapse
Serotonergic synapse
GABAergic synapse
Dopaminergic synapse
Taste transduction
Type II diabetes mellitus
Morphine addiction
Nicotine addiction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group II pathway
Thyrotropin-releasing hormone receptor signaling pathway
Endogenous cannabinoid signaling
GABA-B receptor II signaling
Reactome Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels
WikiPathways Calcium Regulation in the Cardiac Cell
Synaptic Vesicle Pathway
References
Ref 524280ClinicalTrials.gov (NCT01848730) Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia. U.S. National Institutes of Health.
Ref 550563Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.